Erosive esophagitis LA grade A-D Erosive esophagitis, Tegoprazan, KCAB, Esomeprazole, PPI
Conditions
Interventions
Oral tablet Tegoprazan 50 mg once daily ,Oral tablet Esomeprazole 40 mg once daily
Active Comparator Drug,Active Comparator Drug
Tegoprazan,Esomeprazole
Sponsors
Pharmaniaga
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Adults above 18 years old. 2. Experiencing typical GERD symptoms (e.g., heartburn, acid regurgitation). 3. Diagnosed with erosive esophagitis LA classification grade A to D confirmed by upper gastrointestinal endoscopy within 14 days prior to starting study treatment. 4. Patient with positive CLO test.
Exclusion criteria
Exclusion criteria: 1. History of gastrectomy 2. Known case of Baretts oesophagus, eosinophilic oesophagitis, malignancy, or recent upper gastrointestinal bleeding. 3. Known hypersensitivity to tegoprazan, esomeprazole. 4. Pregnant or lactating women. 5. Patients who are already on PPI treatment for within 7 days prior to the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Efficacy of Tegoprazan 8 weeks Oesophagogastroduodenoscopy | — |
Secondary
| Measure | Time frame |
|---|---|
| Onset and degree of symptoms relief between tegoprazan and esomeprazole 8 weeks GERD QRL questionnaire | — |
Countries
Malaysia
Contacts
Public ContactNik Ritza Kosai
National University of Malaysia
Outcome results
None listed